Article
FDA Approves Keytruda for Triple‑Negative Breast Cancer
Rating:
0.0
Views:
83
Likes:
1
Library:
1
FDA Approves Merck's KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10) First Approval for KEYTRUDA in the Breast Cancer Setting November 13, 2020
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value